

Registered Office  
"Maithri",  
No. 132, Cathedral Road,  
Chennai 600 086,  
India.  
CIN: L63011TN2004PLC054948

Tel: 91 44 2811 2472  
URL; [www.ranegroup.com](http://www.ranegroup.com)

## Rane Brake Lining Limited



**//Online Submission//**

RBL/SE/ 25 /2021-22

May 18, 2021

<b>BSE Limited</b> Listing Centre Scrip Code: <b>532987</b>	<b>National Stock Exchange of India Ltd.</b> NEAPS Symbol: <b>RBL</b>
---	---

Dear Sir / Madam,

**Sub: Newspaper publication of Audited Financial Results – Regulation 47 of SEBI LODR**

We hereby enclose copies of extract of the Audited financial results of the Company for the quarter and year ended March 31, 2021 (AFR) published on May 18, 2021, in the newspapers, viz., 'Business Standard' (English) and 'Dinamani' (Regional language).

We request you to take the above on record and note the compliance under relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR).

Thanking you.

Yours faithfully,

**For Rane Brake Lining Limited**

**Venkatraman**  
Secretary

Encl: a/a

# Hospitals to get anti-Covid drugs in June

DRL to manufacture oral drug, which reduces oxygen dependency in patients

AJAI SHUKLA  
New Delhi, 17 May

Defence Minister Rajnath Singh on Monday released the first batch of a keenly awaited anti-Covid-19 drug called 2-deoxy-D-glucose (2-DG). It has been developed by the Defence Research and Development Organisation (DRDO), in partnership with Hyderabad-based private firm Dr Reddy's Laboratories (DRL).

The new drug is not a vaccination, or a preventive measure against being infected by coronavirus. Rather, the 2-DG molecule hastens the recovery of patients who are already suffering from the disease and are, in most cases, facing severe oxygen dependency. The drug is dispensed in powder form in a sachet, and taken orally after being dissolved in water.

Rajnath Singh handed over the first batch of the drug in Delhi to the Minister for Health & Family Welfare, Science & Technology and Earth Sciences, Harsh Vardhan.

DRL Chairman Kallam Satish Reddy said his company would "increase the production capacity of the drug, which is expected to be made available to all hospitals by the first week of June," stated a Ministry of Defence (MoD) release on Monday. Randeep Guleria, director at All India Institute of Medical Sciences (AIIMS), and Lt Gen Sunil Kant of Armed Forces Medical Services (AFMS) were also handed over a box of the drug each.

"More will be handed over to different hospitals across the country for emergency use," the MoD said. The so-called "anti-Covid-19 therapeutic application", which would help patients to reduce oxygen dependency and spend less time in hospital, has been developed by the DRDO laboratory, the Institute of Nuclear Medicine and Allied Sciences (INMAS).

Speaking at the release, the defence minister congratulated DRDO and Dr Reddy's Laboratory for manufacturing the drug. "2-DG drug is a new ray of hope in these challenging times," he said.

Harsh Vardhan, speaking on the occasion, termed 2-DG an important develop-



Union Defence Minister Rajnath Singh hands over to Health Minister Harsh Vardhan the newly launched anti-Covid drug 2DG, developed by DRDO, on Monday

ment that would reduce the recovery time and oxygen dependency in Covid-19 patients. He hoped that the drug would defeat the virus, not just in India but across the globe. The Drugs Controller General of India had granted permission on May 1 for emergency use of this drug as "adjunct therapy in moderate to severe Covid-19 patients."

Rajnath Singh said "the development and production of the drug is a shining example of public-private sector partnership in these challenging times."

The defence minister further said that, when the situation improves, he would personally like to honour the scientists who played a major role in the development of the drug.

Rajnath Singh, who has overseen the military's vigorous response to the second wave of the Covid-19 pandemic, said the government had taken effective steps to provide oxygen, medicines and intensive care unit (ICU) beds in hospitals across the country.

He said country-wide oxygen supply had been substantially increased to more than 9,500 metric tonnes (mt) per day, from around 4,700 mt at the beginning

of May. The defence minister commended the DRDO for setting up medical oxygen plants in hospitals across the country under the PM-CARES Fund. He also praised the DRDO for setting up Covid-19 hospitals, equipped with oxygen, ventilators and ICUs, in Delhi, Ahmedabad, Lucknow, Varanasi and Gandhinagar. Similar hospitals are being set up in Haldwani, Rishikesh, Jammu and Srinagar.

Rajnath Singh also appreciated the passion of retired armed forces doctors who responded to the MoD's call and re-joined service to provide medical care.

He praised the air force and the navy for working tirelessly to transport oxygen tankers, containers, concentrators and other critical medical equipment from abroad and within the country. He highlighted the expansion of Covid-19 treatment facilities at military hospitals which are now being availed by civilians as well.

The defence minister praised the operational orientation of the armed forces, which he said remained alert on the borders even while supporting the civil administration in fighting the second wave.

Business Standard newspaper delivering safely to homes and offices

For details, SMS reachbbs to 57575 or email order@bsmail.in

Business Standard Insight Out

BENGALURU CO-OP. MILK UNION LTD., [BENGALURU DAIRY]  
Dr. M.H. MARIGOWDA ROAD, BENGALURU 560029 :  
E-mail Address bamulpurchase@gmail.com  
Website : www.bamulnandini.coop. Phone : 080- 26096248

BAMUL/PUR/T&C e- Tender-234/2021-22 Date: 12.05.2021  
TECHNICAL CUM COMMERCIAL TENDER THROUGH THE KARNATAKA PUBLIC PROCUREMENT PORTAL

Bengaluru Co-op Milk Union Ltd., (BAMUL) Bengaluru, invites e-tender through e-Procurement Portal from the interested and eligible Manufacturers/ Contractor/Dealer /Distributors for Supply of the following item.

SI	Particulars	Qty	Estd Cost in Lkhs	Tender No
01	Design, Supply, Erection, Testing & Commissioning of Kanakapura dairy expansion Plant & New Skim Milk Powder Plant of Capacity 60 MTPD Along with Utility Expansion on Turnkey Basis at Kanakapura	01 lot	17,900.00	234

1	Access to E-tender Documents	13.05.2021 to 14.06.2021 till 02.00 PM		
2	Pre-Bid Meeting / Tender clarification date & time	31.05.2021 till 11.00 AM		
3	Last date for submission of tender/ quoting	14.06.2021 till 02.00 PM		
4	Date & time for opening Technical Tender	15.06.2021 at 02.35 PM		
5	Date & time for opening Commercial Tender	17.06.2021 at 11.30 AM		
6	Place of opening of Technical and Commercial Tender:	BAMUL (Bengaluru Dairy) Board Room		

The Tenderers shall submit separate tender for the above. Tenderers are advised to note the qualification criteria specified in Section VII to qualify for award of the contract.

The Earnest money deposit (E.M.D.) valid for 45 days beyond the validity of the tender i.e. total for 135 days, Tender processing Fee, modes of e-payment, tender document details and Other details are mentioned in [www.eproc.karnataka.gov.in](http://www.eproc.karnataka.gov.in). Tender No: KMF/BAMUL/PUR/2021-22/234. Sd/ - MANAGING DIRECTOR TENDER INVITING AUTHORITY, BAMUL

**ODISHA GRAMYA BANK**  
INFORMATION TECHNOLOGY DEPARTMENT  
HEAD OFFICE, GANDAMUNDA, PO: KHANDAGIRI, BHUBANESWAR

Bids are invited from prospective bidders for (Re-Tender) RFP to select service integrator for deployment of active directory along with procurement of hardware, software and support services in Odisha Gramya Bank.

For details visit Bank's website: [www.odishabank.in](http://www.odishabank.in)  
RFP ref# OGB/RFP/ITD/AD/002/2021-22, dated 18<sup>th</sup> May 2021  
Last Date & Time of Submission of Bid: 23<sup>rd</sup> June 2021, 15:00 Hours  
Address for Contact: IT Department, Odisha Gramya Bank, Head Office, Gandamunda, Bhubaneswar-751030  
General Manager IT

**ODISHA GRAMYA BANK**  
INFORMATION TECHNOLOGY DEPARTMENT  
HEAD OFFICE, GANDAMUNDA, PO: KHANDAGIRI, BHUBANESWAR

(Re-Tender) Bids are invited from prospective bidders for procurement of 430 units of routers for branches in phased manner. For details visit Bank's website: [www.odishabank.in](http://www.odishabank.in)  
RFP ref# OGB/RFP/ITD/NETWORK/003/2021-22, dated 18<sup>th</sup> May 2021  
Last Date & Time of Submission of Bid: 22<sup>nd</sup> June 2021, 15:00 Hours  
Address for Contact: IT Department, Odisha Gramya Bank, Head Office, Gandamunda, Bhubaneswar-751030  
General Manager IT

## Bleeding and clotting after vaccination minuscule: Govt report

RUCHIKA CHITRAVANSHI  
New Delhi, 17 May

Bleeding and clotting cases following Covid-19 vaccination in India are minuscule but definitive and in line with the expected number of such diagnoses, a report submitted by the national committee on the Adverse Effects Following Immunisation (AEFI) on Monday said.

The government decided to conduct an in-depth analysis of adverse events in India in light of global concerns, the health ministry said. Some countries on March 11 raised an alert on post-vaccination embolic and thrombotic events, particularly with AstraZeneca-Oxford vaccine — Covishield in India, the ministry said.

The reporting rate of these events in India is around 0.61 per million doses, lower than the 4 cases per million reported by UK's regulator Medical and Health Regulatory Authority, Germany has reported 10 events per million doses.

The ministry is issuing advisories to health care workers and vaccine beneficiaries to be aware of suspected thromboembolic symptoms occurring within 20 days after receiving any Covid vaccine, particularly Covishield, and report preferably in the health facility where the dose was given.

The AEFI data in India showed that there is a very minuscule but definitive risk of thromboembolic events. Such events refer to the formation of a clot in a blood vessel that might also break loose and be carried by the bloodstream to plug another vessel. There were no potential thromboembolic events reported following administration of Covaxin vaccine. The committee has completed an in-depth case review of 498 serious and severe events, of which 26 have been reported to be potential thromboembolic events — following the administration of Covishield.

**NOTICE**

**Launch of SBI Fixed Maturity Plan (FMP) - Series 44 (1855 Days)**

Notice is hereby given for launch of SBI Fixed Maturity Plan (FMP) - Series 44 (1855 Days) ("the Scheme"), a close-ended debt scheme. The New Fund Offer (NFO) would be open for subscription from opening of business hours on May 24, 2021 to close of business hours on June 01, 2021. The scheme endeavours to provide regular income and capital growth with limited interest rate risk to the investors through investments in a portfolio comprising of debt instruments such as Government Securities, PSU & Corporate Bonds and Money Market Instruments maturing on or before the maturity of the scheme. The minimum application amount for investment in the Scheme is ₹5000/- and in multiples of ₹1/- thereafter. The Scheme has two Plans – Regular and Direct. Both the plans have two options viz. Growth and Income Distribution cum capital withdrawal (IDCW). No repurchase /redemption of the units shall be allowed before the maturity of the Scheme and the Scheme would be listed on BSE Limited (BSE) in order to provide liquidity. For more information on the Scheme, you are requested to get in touch with the nearest Official Point of Acceptance of SBI Mutual Fund.

**This product is suitable for investors who are seeking\*:**

- Income with capital growth over the tenor of the scheme
- Investment in Debt / Money Market Instrument / Govt. Securities

\*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

**For SBI Funds Management Private Limited**  
Sd/-  
**Vinay M. Tonse**  
Managing Director & CEO

**Asset Management Company:** SBI Funds Management Private Limited (A Joint Venture between SBI & AMUNDI) (CIN: U65909MH1992PTC065289) **Trustee:** SBI Mutual Fund Trustee Company Pvt. Ltd. (CIN: U65909MH2003PTC138496) **Sponsor:** State Bank of India **Regd Office:** 9<sup>th</sup> Floor, Crescendo, C - 38 & 39, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 **Tel:** 91-22-61793000 • **Fax:** 91-22-67425687 • **E-mail:** partnerforlife@sbfm.com • [www.sbfm.com](http://www.sbfm.com)

**BSE Disclaimer:** It is to be distinctly understood that the permission given by BSE Ltd. should not in any way be deemed or construed that the Scheme Information Document has been cleared or approved by BSE Ltd. nor does it certify the correctness or completeness of any of the contents of the Scheme Information Document. The investors are advised to refer to the Scheme Information Document for the full text of Disclaimer Clause of BSE Ltd.

**Mutual Fund investments are subject to market risks, read all scheme related documents carefully.** SBIMF/2021/MAY/03

**Rane BRAKE LINING LIMITED**  
CIN: L63011TN2004PLC054948  
Regd. Office: "MAITHRI", 132, Cathedral Road, Chennai - 600 086. Visit us at: [www.ranegroup.com](http://www.ranegroup.com)

**Extract of Audited Financial Results for the quarter and year ended March 31, 2021**

S. No.	Particulars	Rs. in Lakhs			
		Quarter Ended		Year Ended	
		31.03.2021	31.03.2020	31.03.2021	31.03.2020
1.	Total income from operations (net)	15,236.60	11,984.95	43,481.01	48,143.01
2.	Net Profit / (Loss) for the period (before Tax and Exceptional items)	2,116.16	1,435.20	4,693.83	4,468.10
3.	Net Profit / (Loss) for the period before tax (after Exceptional items)	2,116.16	1,435.20	4,693.83	4,468.10
4.	Net Profit / (Loss) for the period after tax (after Exceptional items)	1,427.30	932.31	3,180.48	3,434.50
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,466.57	899.55	3,248.27	3,336.49
6.	Equity Share Capital	775.24	791.50	775.24	791.50
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year			22,991.22	22,091.44
8.	Earnings Per Share (of Rs.10/- each)				
	(a) Basic :	18.39	11.78	40.45	43.39
	(b) Diluted:	18.39	11.78	40.45	43.39

**Note:**

- The above is an extract of the detailed format of Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the Stock Exchange websites: [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and on the Company's website-[www.ranegroup.com](http://www.ranegroup.com).
- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 17, 2021.
- During the year ended March 31, 2021, the Company bought back 1,62,621 Equity shares of Rs. 10/- each for an aggregate amount of Rs. 1188.37 lakhs. Further, the Company has transferred Rs. 16.26 lakhs to the Capital redemption reserve. Consequently to the Buyback, the paid-up Equity share capital has reduced by Rs. 16.26 lakhs and stands at Rs. 7,75,23,590/- consisting of 77,52,359 Equity shares of Rs. 10/- each. Out of 1,62,621 Equity shares bought back, shares to the extent of 7,756 nos were extinguished in subsequent financial year.
- The results for the current year are not comparable as such with that of the previous year on account of Covid 19 pandemic, which impacted the economy in general and also the operations of the company. The company, based on the internal and external information available up to the date of approval of these financial results, has concluded that no adjustments are required in the carrying amounts of property, plant and equipment, inventories, trade receivables and other financial assets. However, given the uncertainties associated with the nature and duration of the pandemic, actual results may differ from those estimated as at the date of approval of the financial statements. The company will continue to monitor future economic conditions and update its assessment.
- The Board of Directors have recommended a Dividend of Rs.25 per equity share for the year ended March 31, 2021.

For Rane Brake Lining Limited  
L Ganesh  
Chairman

Place : Chennai  
Date : May 17, 2021

**ONGC Mangalore Refinery and Petrochemicals Limited**  
(A Govt. of India Enterprise and A Subsidiary of ONGC Limited)  
CIN - L23209KA1988GOI008959  
Regd. Office: Mudapadav, Kuthethoor P.O., Via Katipalla, Mangaluru - 575 030, Karnataka.

**EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021**  
(All amounts are in ₹ in Crore except per share data)

SL. NO.	Particulars	STANDALONE		CONSOLIDATED	
		Quarter Ended		Year Ended	
		31.03.2021	31.03.2020	31.03.2021	31.03.2020
1	Total Income from Operations	20,788.05	17,545.07	51,019.19	60,751.54
2	Net Profit / (Loss) for the period (before Tax and Exceptional items)	518.90	(2,275.90)	(345.10)	(3,957.50)
3	Net Profit / (Loss) for the period before tax (after Exceptional items)	518.90	(2,275.90)	(345.10)	(3,957.50)
4	Net Profit / (Loss) for the period after tax (after Exceptional items)	328.30	(1,629.14)	(240.46)	(2,740.35)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	336.73	(1,634.32)	(238.46)	(2,748.92)
6	Paid up Equity Share Capital (Face Value of ₹ 10/- each)	1,752.60	1,752.60	1,752.60	1,752.60
7	Other equity			5,775.70	6,014.17
8	Earnings Per Share (EPS) (Face value of ₹ 10/- each) (for continuing operations) (not annualised)				
	a) Basic (₹)	1.87	(9.30)	(1.37)	(15.64)
	b) Diluted (₹)	1.87	(9.30)	(1.37)	(15.64)

^ Restated  
**Notes:**

- The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with Stock Exchanges under Regulation 33 of the SEBI (Listing and other Disclosure Requirements) Regulations, 2015. The detailed financial results and this extract were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 17, 2021. The full format of Quarterly/ Annual Financial Results are available on the Stock Exchange websites ([www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)) and Company's website [www.mrpl.co.in](http://www.mrpl.co.in).
- The financial results of the Company and the Group have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended). These financial results have been prepared in accordance with the recognition and measurement principles of Ind AS, prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- The financial results have been audited by the Joint Statutory Auditors as required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.
- The Audited Accounts are subject to Supplementary Audit by the Comptroller and Auditor General of India under section 143(6) of the Companies Act, 2013.
- In continuation to the Board approval in the 232nd meeting for acquisition of 1,24,66,53,746 equity shares of ₹ 10 each of ONGC Mangalore Petrochemicals Limited (OMPL), a subsidiary of the Company from Oil and Natural Gas Corporation Limited (ONGC) (an existing shareholder of OMP) held on October 19, 2020, subsequently a Share Purchase Agreement (SPA) was executed with ONGC for acquisition of 124,66,53,746 equity shares of ₹ 10/- each of OMP from ONGC. An amount of ₹ 1,216.73 crore was paid to ONGC towards consideration for acquisition of 124,66,53,746 equity shares at a price of ₹ 9.76 per share. As per the SPA, ONGC transferred 124,66,53,746 shares of OMP to MRPL's demat Account on January 1, 2021. With this, shareholding of MRPL in OMP has increased to 99.998% w.e.f. January 1, 2021. The details are available on the websites of NSE and BSE at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) respectively and on the Company's website at [www.mrpl.co.in](http://www.mrpl.co.in).

For and on behalf of the Board  
Sd./- POMILA JASPAL  
Director (Finance)  
DIN: 08436633

Place : New Delhi  
Date : 17/05/2021

**Note:** 1) SEBI has mandated that request for effecting transfer of shares shall not be processed unless the shares are held in dematerialised form with a depository. In view of this, Shareholders holding shares in physical form are requested to open Demat Account with a Depository and dematerialise the shares for easy liquidity.  
2) Shareholders are further requested to complete their KYC formalities at the earliest. Shareholders holding shares in dematerialised form are requested to update their email IDs with their respective DPs to receive the communication from the Company on emails.

**Together, Let us build a Clean India**

**WABCO INDIA LIMITED**  
CIN:L34103TN2004PLC054667  
Registered Office: Plot No.3 (SP), III Main Road, Ambattur Industrial Estate, Chennai 600058  
Ph.91 44 42242000, Fax .91 44 42242009,  
[www.wabco-auto.com](http://www.wabco-auto.com), email: [cvcs.info.india@zf.com](mailto:cvcs.info.india@zf.com)

**STATEMENT OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2021**  
(Rupees in lakhs except EPS)

Particulars	Quarter ended		Year ended	
	31.03.2021	31.12.2020	31.03.2019	31.03.2020
	(Audited)	(Unaudited)	(Audited)	(Audited)
Total income from operations	71,891.25	57,431.40	42,298.51	190,238.87
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	4,763.37	5,242.97	3,149.61	10,380.49
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	4,763.37	5,242.97	3,149.61	10,380.49
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	4,763.37	5,242.97	3,149.61	10,380.49
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	4,997.28	5,108.27	3,300.73	10,185.59
<b>Equity Share Capital</b>				
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year				198,691.96
<b>Earnings Per Share (of Rs. 5/- each) (for continuing and discontinued operations) -</b>				
Basic	25.11	27.64	16.61	54.73
Diluted	25.11	27.64	16.61	54.73

**Notes:**

- The above financial results for the quarter and year ended 31 March, 2021 were reviewed by the Audit Committee and upon its recommendation, were approved by the Board of Directors at its meeting held on May 17, 2021. The above results for the year ended 31 March, 2021 have been subjected to an audit by the statutory auditor of the Company.
- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("IndAS") as prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules, 2015, as amended.
- Revenue from operations include the following:

	Quarter ended		Year ended	
	31.03.2021	31.12.2020	31.03.2019	31.03.2020
Sales of Products	66,431.59	51,905.33	35,868.11	166,642.54
Others	4,800.73	4,744.31	4,617.28	19,707.47
<b>Total</b>	<b>71,232.32</b>	<b>56,649.64</b>	<b>40,485.39</b>	<b>186,350.01</b>

- The Company operates in one segment, namely automotive components and allied services.
- During the year ended March 31, 2021, management has identified certain instances of alleged irregularities in disbursement/ settlement of provident fund dues paid out of the Employees' Provident Fund Trust ("the Trust") and salary payments to fixed-tenure employees in the current and earlier years. In this regard, the Company has initiated investigation of such alleged irregularities relating to payments from the Trust and other payments from the Company to employees by engaging an external independent expert through a law firm and is also evaluating necessary actions. Pending completion of the aforesaid investigation, the management has made a preliminary assessment and has recorded a provision of INR 500 lakhs in these annual financial results. The auditors have qualified their audit report in this regard.
- The figures of the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial year which was subjected to a limited review.
- The Board of Directors has recommended a dividend payment of Rs. 11/- per share (Face value Rs. 5/- each) for the year ended March 31, 2021.
- The figures for the previous period / year, have been reclassified wherever necessary to conform to the current period's year's classification.

For and on behalf of the board  
P Kanian  
Managing Director

Chennai  
May 17, 2021

